119 related articles for article (PubMed ID: 38480077)
1. Different diagnostic strategies combining prostate health index and magnetic resonance imaging for predicting prostate cancer: A multicentre study.
Zhu M; Fu Q; Zang Y; Shao Z; Zhou Y; Jiang Z; Wang W; Shi B; Chen S; Zhu Y
Urol Oncol; 2024 May; 42(5):159.e17-159.e23. PubMed ID: 38480077
[TBL] [Abstract][Full Text] [Related]
2. The Prostate Health Index and multi-parametric MRI improve diagnostic accuracy of detecting prostate cancer in Asian populations.
Ye C; Ho JN; Kim DH; Song SH; Kim H; Lee H; Jeong SJ; Hong SK; Byun SS; Ahn H; Hwang SI; Lee HJ; Lee S
Investig Clin Urol; 2022 Nov; 63(6):631-638. PubMed ID: 36347552
[TBL] [Abstract][Full Text] [Related]
3. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
[TBL] [Abstract][Full Text] [Related]
4. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
Kim L; Boxall N; George A; Burling K; Acher P; Aning J; McCracken S; Page T; Gnanapragasam VJ
BMC Med; 2020 Apr; 18(1):95. PubMed ID: 32299423
[TBL] [Abstract][Full Text] [Related]
5. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
6. A multi-institutional study of 1,111 men with 4K score, multiparametric magnetic resonance imaging, and prostate biopsy.
Thomas J; Atluri S; Zucker I; Reis I; Kwon D; Kim E; Tewari A; Patel V; Wagaskar V; Konety B; Kasraeian A; Czarniecki S; Thoreson G; Soodana-Prakash N; Ritch C; Nahar B; Gonzalgo M; Kava B; Parekh D; Punnen S
Urol Oncol; 2023 Oct; 41(10):430.e9-430.e16. PubMed ID: 37544833
[TBL] [Abstract][Full Text] [Related]
7. External validation and comparison of magnetic resonance imaging-based predictive models for clinically significant prostate cancer.
Lee HJ; Lee A; Yang XY; Law YM; Huang HH; Lau WK; Lee LS; Ho HS; Cheng CW; Yuen JS; Tay KJ; Chen K
Urol Oncol; 2021 Nov; 39(11):783.e1-783.e10. PubMed ID: 33775528
[TBL] [Abstract][Full Text] [Related]
8. Natural History of Patients with Prostate MRI Likert 1-3 and Development of RosCaP: a Multivariate Risk Score for Clinically Significant Cancer.
Orecchia L; Nardi A; Fletcher P; Ippoliti S; Grounds J; Dokubo I; Spicchiale CF; Miah S; Miano R; Barrett T; Kastner C
Clin Genitourin Cancer; 2023 Feb; 21(1):162-170. PubMed ID: 35970760
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of prostate cancer identified by transperineal standard template biopsy in men with nonsuspicious multiparametric magnetic resonance imaging.
Dahl DM; Wu S; Lin SX; Hu M; Barney AA; Kim MM; Cornejo KM; Harisinghani MG; Feldman AS; Wu CL
Urol Oncol; 2024 Feb; 42(2):28.e21-28.e28. PubMed ID: 38182499
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
11. Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population.
Hsieh PF; Li WJ; Lin WC; Chang H; Chang CH; Huang CP; Yang CR; Chen WC; Chang YH; Wu HC
World J Urol; 2020 May; 38(5):1207-1214. PubMed ID: 31440806
[TBL] [Abstract][Full Text] [Related]
12. The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy.
Stejskal J; Adamcová V; Záleský M; Novák V; Čapoun O; Fiala V; Dolejšová O; Sedláčková H; Veselý Š; Zachoval R
World J Urol; 2021 Jun; 39(6):1889-1895. PubMed ID: 32761380
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: The role of systematic and targeted biopsies.
Filson CP; Natarajan S; Margolis DJ; Huang J; Lieu P; Dorey FJ; Reiter RE; Marks LS
Cancer; 2016 Mar; 122(6):884-92. PubMed ID: 26749141
[TBL] [Abstract][Full Text] [Related]
14. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years.
Boegemann M; Stephan C; Cammann H; Vincendeau S; Houlgatte A; Jung K; Blanchet JS; Semjonow A
BJU Int; 2016 Jan; 117(1):72-9. PubMed ID: 25818705
[TBL] [Abstract][Full Text] [Related]
15. In-parallel comparative evaluation between multiparametric magnetic resonance imaging, prostate cancer antigen 3 and the prostate health index in predicting pathologically confirmed significant prostate cancer in men eligible for active surveillance.
Porpiglia F; Cantiello F; De Luca S; Manfredi M; Veltri A; Russo F; Sottile A; Damiano R
BJU Int; 2016 Oct; 118(4):527-34. PubMed ID: 26350955
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
17. The use of 29 MHz transrectal micro-ultrasound to stratify the prostate cancer risk in patients with PI-RADS III lesions at multiparametric MRI: A single institutional analysis.
Avolio PP; Lughezzani G; Paciotti M; Maffei D; Uleri A; Frego N; Hurle R; Lazzeri M; Saita A; Guazzoni G; Casale P; Buffi NM
Urol Oncol; 2021 Dec; 39(12):832.e1-832.e7. PubMed ID: 34183255
[TBL] [Abstract][Full Text] [Related]
18. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
Schwen ZR; Mamawala M; Tosoian JJ; Druskin SC; Ross AE; Sokoll LJ; Epstein JI; Carter HB; Gorin MA; Pavlovich CP
BJU Int; 2020 Sep; 126(3):373-378. PubMed ID: 32367635
[TBL] [Abstract][Full Text] [Related]
19. The Prostate Health Index adds predictive value to multi-parametric MRI in detecting significant prostate cancers in a repeat biopsy population.
Gnanapragasam VJ; Burling K; George A; Stearn S; Warren A; Barrett T; Koo B; Gallagher FA; Doble A; Kastner C; Parker RA
Sci Rep; 2016 Oct; 6():35364. PubMed ID: 27748407
[TBL] [Abstract][Full Text] [Related]
20. Measurement of serum isoform [-2]proPSA derivatives shows superior accuracy to magnetic resonance imaging in the diagnosis of prostate cancer in patients with a total prostate-specific antigen level of 2-10 ng/ml.
Furuya K; Kawahara T; Narahara M; Tokita T; Fukui S; Imano M; Mitome T; Ito Y; Izumi K; Osaka K; Yokomizo Y; Hayashi N; Hasumi H; Nawata S; Kawano T; Yao M; Uemura H
Scand J Urol; 2017 Aug; 51(4):251-257. PubMed ID: 28351193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
